↓ Skip to main content

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer

Overview of attention for article published in Frontiers in Pharmacology, April 2021
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
Published in
Frontiers in Pharmacology, April 2021
DOI 10.3389/fphar.2021.665253
Pubmed ID
Authors

Luwei Han, Xiaomeng Zhang, Zhiqiang Wang, Xian Zhang, Liwen Zhao, Wei Fu, Xiaobo Liang, Zhibo Zhang, Yong Wang

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 27%
Student > Ph. D. Student 1 9%
Professor 1 9%
Student > Master 1 9%
Professor > Associate Professor 1 9%
Other 0 0%
Unknown 4 36%
Readers by discipline Count As %
Immunology and Microbiology 1 9%
Neuroscience 1 9%
Chemistry 1 9%
Medicine and Dentistry 1 9%
Unknown 7 64%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 May 2021.
All research outputs
#14,267,331
of 23,308,124 outputs
Outputs from Frontiers in Pharmacology
#4,499
of 16,753 outputs
Outputs of similar age
#219,584
of 437,171 outputs
Outputs of similar age from Frontiers in Pharmacology
#245
of 889 outputs
Altmetric has tracked 23,308,124 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,753 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,171 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 889 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.